Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.

Mina Mirzaee; Setareh Haghighat; Bahareh Golkaran; Fatemeh Asgarhalvaei; Rayhaneh Mirzaee; Morteza Taghizadeh; Mohammad Ali Savoji; Behzad Esfandiari; Mehdi Mahdavi

Return

Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.

Author: Mina MIRZAEE ¹ ; Setareh HAGHIGHAT ¹ ; Bahareh GOLKARAN ¹ ; Fatemeh ASGARHALVAEI ¹ ; Rayhaneh MIRZAEE ² ; Morteza TAGHIZADEH ³ ; Mohammad Ali SAVOJI ¹ ; Behzad ESFANDIARI ^{4
,

5} ; Mehdi MAHDAVI ^{6
,

7
,

8
,

9}
Author Information

1. Department of Microbiology, Faculty of Advanced Sciences & Technology, Tehran Medical Sciences, Islamic Azad University, (IAUPS), Tehran, Iran.
2. Department of Biotechnology, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS).
3. Department of Medical vaccine, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
4. Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran
5. Department of Laboratory Animal Science, Pasteur Institute of Iran, Karaj, Iran.
6. Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
7. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
8. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
9. Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Publication Type:Journal Article
Keywords: HBsAg; Long-lasting humoral response; Montanide ISA-720; Naloxone; Vaccine
MeSH: Adjuvants, Immunologic/pharmacology*; Alum Compounds; Animals; Cytokines; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Immunity, Humoral; Immunoglobulin G; Interleukin-2; Interleukin-4; Mice; Mice, Inbred BALB C; Mineral Oil; Naloxone/pharmacology*; Tumor Necrosis Factor-alpha
From: Biomedical and Environmental Sciences 2022;35(9):792-803
CountryChina
Language:English
Abstract: OBJECTIVE:This study aimed to investigate the effects of Montanide ISA-720 and Naloxone (NLX) in Hepatitis B surface antigen (HBsAg) vaccine formulation on cytokine and long-lasting antibody responses.
METHODS:First, the HBsAg was formulated in Montanide ISA-720 adjuvant and Naloxone at 5 and 10 mg/kg. The experimental mice were immunized three times at a 2-week interval, and then IL-4, IL-2, TNF-α, and IFN-γ cytokines; long-lasting IgG antibody responses 220 days after the last shot; and IgG1/IgG2a isotypes were assessed by ELISA.
RESULTS:The HBsAg-Alum group exhibited the highest IL-4 cytokine response among the experimental groups, whereas NLX in HBsAg-MON720 vaccine formulation did not affect cytokine responses. In addition, NLX in Alum-based vaccine suppressed IL-4 cytokine response and increased the IL-2/IL-4 cytokine ratio. Moreover, HBsAg-MON720 was more potent than HBsAg-Alum in the induction of antibody responses, and NLX in Alum- and MON720-based vaccines induced long-lasting antibody responses.
CONCLUSION:NLX in Alum-based vaccine decreased IL-4 cytokine response, increased IL-2/IL-4 cytokine ratio, and improved long-lasting humoral immune responses in both vaccine formulations. Therefore, the adjuvant activity of NLX in the vaccine formulation depends on the type of adjuvant and the nature of the antigen in the vaccine formulation.